
Denovo Biopharma appears to think that Lundbeck's hand-me-downs are quite the treasure trove.
The companies have made a deal that Denovo will be in-licensing rights to the drug candidate idalopirdine, which Lundbeck formerly developed as a treatment for Alzheimer's disease. This drug was officially shelved in 2017 after a failed phase III study towards the end of the previous year, which also caused the company's share price to plummet.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app